Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Stay positive, 2017 should be a solid year with two potential outcomes, both of which are good for ADXS and its shareholders:

1) Dan decides to focus on creating shareholder value, delivering solid catalysts that reset our valuation upward without any questionable activity that ends up hurting shareholder value while catering to management's financial interests.

2) Dan continues to fail to deliver shareholder value, at which time on December 31, 2017 he is asked to resign and replaced by a veteran biotech leader with a demonstrated track record of creating value for shareholders.

GLTA